🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excellent result with RF/PF ablation using the lattice tip catheter at LBCT #AFSymposium2021

Real-time RF/PF case by Vivek Reddy at #AFSymposium2021

cardiacrhythmnews.com/af-symposium-2…

Persistent AF case with Affera: PVI+Mitral Line+PWI+CTI with transpired therapy time of 30 min. Multiple cases, durable lines, consistent results. High-Res mapping and PFA/RFA from the same lattice catheter at a switch of a button. Exciting times to be in EP and Cleveland Clinic

Another PerAF case with Affera PFA: PVI+PWI+MAL: 1st to last lesion <30min with total procedure time <1Hr including mapping and 20min waiting period (no reconnections). We may soon be ready to re-evaluate ablation strategies to treat different types of AF w/ rapid and durable Tx.

Affera ready to redefine another catheter ablation category. Thank you Drs. Aidietis and Račkauskas at Vilnius University Hospital for hosting us and Elad Anter and Vivek Y. Reddy for joining us to perform successful FIH procedures last week. Stay tuned…

Affera, Inc. Announces Successful First-In-Human Use Of SpherePVI Circumferential Pulmonary Vein Isolation Device ... prn.to/3zGJ3jj

Dose dependent reversible electroporation - effect on AV node conduction. Follow up from last years data on egm amplitude - transient AV block after the pulse that reverses in <1-2 minutes

Great paper by Elad Anter group at Cleveland Clinic with Affera Sphere9 #latticetip catheter

*New Research Article* - Pulsed-Field Ablation in Ventricular Myocardium Using a Focal Catheter Elad Anter #AHAJournals #Epeeps doi.org/10.1161/CIRCEP…

#EPeeps - SinaiNYC- having fun and hoping to improve efficacy and safety

First patient treated in US IDE SPHERE PerAF at Mount Sinai Health System by Drs. Vivek Y. Reddy Jacob Koruth William Whang and others. Affera also announces $75M series C with Bain Capital Life Sciences. prnewswire.com/news-releases/…

This is an exciting day for the Affera, Inc. team. Looking forward to partnering with Medtronic to improve therapies for cardiac arrhythmia patients worldwide. prnewswire.com/news-releases/…

Thank you Drs ⁦Elad Anter⁩, Taigen et al. Cleveland Clinic⁩, ⁦Andrea Natale MD⁩ , Burkhardt et al. ⁦Texas Cardiac Arrhythmia Institute⁩ and ⁦⁦Moussa Mansour⁩ et al. ⁦Harvard Medical School⁩ for a busy and exciting week for ⁦Affera⁩ SPHERE PersAF trial!

I am fortunate to be a site prinicipal investigator for AFFERA's disruptive pulse-field/radiofrequency atrial fibrillation ablation clinical trial. The cardiac electrophysiology community across the world is looking forward to this trial. I had our cent…lnkd.in/e36Sdvyc

Thoughts after first cases w Affera: 1) having all in one mapping/ablating globe is super efficient (mapped an LAA AT and two SVC ATs on first case- first burn terminations on all three) 2) mapping definition and annotation algorithm is on the money as evidenced above

Keep up with Affera technologies and clinical programs via Medtronic Channels: Medtronic Cardiac and Medtronic Structural Heart starting today!

Just published! The Affera™ Mapping and Ablation System 12-month outcomes that led to CE Mark were just published in JACC Journals. Read it now: bit.ly/3oC4F03

Thrilled the first Affera System case took place at Medical Center Hamburg-Eppendorf. Congrats to Andreas Metzner & team. This is the first of sites to come in the next few weeks. Excited to make a difference for patients with this novel innovation #MedtronicEmployee #EPeeps